Atlas Trials

A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

Clinical trial NCT02969369 · COMPLETED

Trial details

NCT number
NCT02969369
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Parkinson Disease Psychosis
Start date
2016-12-31
Primary completion
2020-04-20
Enrollment
39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.